Edward M. MD Kaye - Mar 15, 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
CEO, Director
Signature
/s/ Jonathan Allan, Attorney-in-Fact
Stock symbol
STOK
Transactions as of
Mar 15, 2025
Transactions value $
$0
Form type
4
Date filed
3/18/2025, 04:07 PM
Previous filing
Jan 6, 2025
Next filing
Mar 20, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise $0 +35.5K +36.64% $0.00 132K Mar 15, 2025 Direct
transaction STOK Common Stock Options Exercise $0 +26.3K +19.83% $0.00 159K Mar 15, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Restricted Stock Units Options Exercise $0 -35.5K -33.33% $0.00 71K Mar 15, 2025 Common Stock 35.5K Direct F1, F2
transaction STOK Restricted Stock Units Options Exercise $0 -26.3K -25% $0.00 78.8K Mar 15, 2025 Common Stock 26.3K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F2 The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date.
F3 The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date.